Share ownership Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 16:00:02 2026-03-06 EST			5-day change	1st Jan Change
115.79 ^USD	-0.24%		-6.49%	+10.00%

03-06	Top pharma companies racing to launch a weight-loss pill	RE
03-04	Health Rounds: Laser treatment before immunotherapy helps brain cancer patients live longer	RE

Share class: Merck & Co., Inc.

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	3,577,103,522	2,528,032,964 ( 70.67 %)	1,045,073,377 ( 29.22 %)	70.67 %

Major shareholders: Merck & Co., Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 10.25 %	254,322,763	10.25 %	28 044 M $
BlackRock Advisors LLC 6.484 %	160,933,559	6.484 %	17 746 M $
STATE STREET CORPORATION 4.836 %	120,040,168	4.836 %	13 237 M $
Wellington Trust Co., NA 3.482 %	86,435,458	3.482 %	9 531 M $
Geode Capital Management LLC 2.419 %	60,047,984	2.419 %	6 621 M $
BlackRock Life Ltd. 2.072 %	51,436,428	2.072 %	5 672 M $
Charles Schwab Investment Management, Inc. 1.957 %	48,563,804	1.957 %	5 355 M $
Eaton Vance Management 1.811 %	44,946,021	1.811 %	4 956 M $
Fidelity Management & Research Co. LLC 1.643 %	40,767,953	1.643 %	4 495 M $
Norges Bank (13F) 1.53 %	37,981,502	1.53 %	4 188 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Caixa DTVM SA 0.001085 %	215,530	0.001085 %	3 M $
Safra Asset CTVM SA (Investment Management) 0.000293 %	58,100	0.000293 %	805 214 $
XP Allocation Asset Management Ltda. 0.000027 %	5,293	0.000027 %	73 356 $
E2M Investimentos Ltda. 0.000004 %	700	0.000004 %	9 701 $

Breakdown by shareholder type

Institutional	63.83%
Other	8.49%
State Street Corp.	4.84%
Swedbank AB	0.31%
Sumitomo Mitsui Trust Group, Inc.	0.28%
Schweizerische Nationalbank	0.28%
Governments	0.15%
SEI Investments Co.	0.11%
The Bank of Nova Scotia	0.08%
Danske Bank A/S	0.08%
Manulife Financial Corp.	0.07%
Skandinaviska Enskilda Banken AB	0.07%
Regions Financial Corp.	0.05%
Individuals	0.05%
Münchener Rückversicherungs-Gesellschaft AG	0.04%
ING Groep NV	0.03%
First Financial Bankshares, Inc.	0.03%
Old Republic International Corp.	0.03%
Banco Bilbao Vizcaya Argentaria SA	0.02%
Zurich Insurance Group AG	0.02%
Fifth Third Bancorp	0.02%
Peapack-Gladstone Financial Corp.	0.02%
ABN AMRO Bank NV	0.01%
Ally Financial, Inc.	0.01%
The Allstate Corp.	0.01%
Fairfax Financial Holdings Ltd.	0.01%
Cullen/Frost Bankers, Inc.	0.01%
Silvercrest Asset Management Group, Inc.	0.01%
Rathbones Group Plc	0.01%
Hancock Whitney Corp.	0.01%
Commerzbank AG	0.01%
Unknown	21.01%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	59.44%
United Kingdom	7.83%
Canada	2.4%
Norway	1.73%
Sweden	1.03%
France	0.96%
Australia	0.79%
Japan	0.79%
Switzerland	0.75%
Denmark	0.66%
Germany	0.48%
Hong Kong	0.35%
Netherlands	0.34%
South Korea	0.31%
Ireland	0.19%
Italy	0.18%
Luxembourg	0.16%
Belgium	0.1%
Spain	0.09%
Finland	0.09%
New Zealand	0.07%
Individuals	0.05%
Austria	0.05%
Singapore	0.05%
Czech Republic	0.03%
Liechtenstein	0.02%
Saudi Arabia	0.01%
Brazil	0.01%
Puerto Rico	0.01%
South Africa	0.01%
Slovenia	0.01%
China	0.01%

Based on 1000 largest holdings

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (69.4%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (20%); - sale of animal health products (9.2%); - other (1.4%). Net sales are distributed geographically as follows: the United States (50.3%), Europe/Middle East/Africa (21.8%), Latin America (5.4%), China (8.6%), Japan (5.1%), Asia/Pacific (4.8%) and other (4%).

Employees

74,000

Sector

Pharmaceuticals

Calendar

03-16 - Ex-dividend date - 0.85 USD

More about the company